SUMMARY
Captopril (SQ 14225), an orally active converting enzyme inhibitor, was administered in a dose of 50mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II), and 8 renovascular hypertensive patients (Group III). In Group III, 5 of the 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of captopril was greater in 7 of the 8 patients than those in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia.
It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.
Additional Indexing Words: Angiotensin I converting enzyme inhibitor Screening test Essential hypertension Cardiovascular response HE determination of plasma renin activity (PRA) before and after provocating maneuvers of renin release such as tilting,1) sodium depletion2) or administration of diuretics3) or vasodilators4) is useful for diagnosis of renovascular hypertension and predicting the surgical curability. In some patients with renovascular hypertension, however, such maneuvers fail to stimulate the release of renin.5), 6) Recently, it has been reported that specific antagonists of angiotensin II or angiotensin I converting enzyme inhibitors (AICEI) augment the PRA.7)-9) Re et al10) reported that SQ 20881, an AICEI, enhanced the difference in PRA of the renal vein between the affected side and the intact side in hypertensive patients with unilateral renovascular disease. Gavras et al11) reported that the increment of PRA 7 days after the administration of a fixed dose of captopril (SQ 14225), an orally active AICEI, was much greater in patients with renovascular hypertension than in patients with essential hypertension.
The purpose of this study is to examine the response of renin secretion to acute administration of captopril in essential and renovascular hypertension and to see if this provocation test of renin release is useful for the diagnosis of renovascular hypertension.
MATERIALS AND METHODS

Patients
Studies were performed in normotensive subjects (Group I), patients with essential hypertension (Group II), and patients with renovascular hypertension (Group III). Subjects in Group I (12 men), ranging in age from 31 to 51 years, showed no evidence of significant cardiovascular disease, and their mean arterial blood pressures (MAP) ranged from 88 to 105mmHg at the time of study. Patients in Group II consisted of 8 women and 18 men ranging in age from 32 to 64 years. Routine screening tests for secondary hypertension including intravenous pyelography, 131I-Hippuran renography, 99mTechnetium renoscintigraphy, plasma renin activity and plasma aldosterone concentration were performed in all of these patients. As a rule, aortography was performed in Group II to rule out the renal vascular lesion. Details of clinical data in Group III are shown in Table I . The etiological diagnosis of stenotic lesions was tentatively made by angiographic find- Jp n. Heart J. November, 1980 Fig. 1 . PRA response to 50mg of captopril in normotensive subjects. Abbreviations:
C=control; SQ1=1 hour after captopril administration; SQ2=2 hours after captopril administration. 4) . Fig. 4 . Relation of control PRA to that 2 hours after captopril administration. Open squares, normotensive subjects. Solid circles, essential hypertensive patients.
Open circles, renovascular hypertensive patients. Open triangle, the Case 8 of Table I . Goldblatt hypertension in animal models in which renin-angiotensin system seemed to be not important.16) Such a patient is very rare in renovascular hypertension. Our data, therefore, indicate that the provocation test described here represents an useful screening for detecting renovascular hypertension among hypertensive patients. This conclusion is consistent with the study of Case et al.17) They reported that diagnostic discrimination was greately enhanced by infusion of salarasin or SQ 20881, which elicited marked reactive hyperreninemia in renovascular hypertensive patients. All the patients with renovascular hypertension showed a hyper-response in renin release to captopril even during the treatment with antihypertensive agents such as propranolol, clonidine, and alphamethyldopa, suggesting that this provocation test may also be used in hypertensive patients under antihypertensive medication. The test can be applied as well in hypertensive patients on an unrestricted sodium diet.
The provocation test presented here should be performed under careful monitoring of blood pressure to avoid too precipitous hypotension not infrequently induced in high renin patients by AICEI. 18) In the present data, there was no significant difference in the reduction of MAP between renovascular hypertensive group and essential hypertensive group. However, these data do not exclude the possibility that captopril could induce greater reduction of perfusion pressure in the post-stenotic legion of the kidney in renovascular hypertension than in essential hypertension, which, in turn, could produce a greater increase in PRA in the former than in the latter, although the renal perfusion pressure was not measured in this study.
It has been shown that AICEI increases the renin release through its interception of negative short feedback mechanism of the renin release.7),9) Therefore, there is a possibility that this negative short feedback mechanism may be different in renovascular hypertension from that in essential hypertension, thus causing the hyper-response in the renin release to captopril in renovascular hypertension, though there was no proof for this hypothesis.
In summary, the oral administration of 50mg of captopril produced the hyper-response in the renin release in all patients except one with renovascular hypertension in this study. These data indicate that this provocation test may be useful as a screening procedure for the diagnosis of renovascular hypertension.
